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The aryl hydrocarbon receptor (AhR) is a soluble, ligand-activated transcription factor that mediates the toxicity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Increasing evidence implicates the AhR in regulating extracellular matrix (ECM)
homeostasis. We recently reported that TCDD increased necroinflammation and myofibroblast activation during liver injury
elicited by carbon tetrachloride (CCl
4
). However, TCDD did not increase collagen deposition or exacerbate fibrosis in CCl
4
-treated
mice, which raises the possibility that TCDD may enhance ECM turnover. The goal of this study was to determine how TCDD
impacts ECMremodeling gene expression in the liver.Male C57BL/6micewere treated for 8weekswith 0.5mL/kgCCl
4
, andTCDD
(20𝜇g/kg) was administered during the last two weeks. Results indicate that TCDD increased mRNA levels of procollagen types I,
III, IV, and VI and the collagen processing molecules HSP47 and lysyl oxidase. TCDD also increased gelatinase activity andmRNA
levels of matrix metalloproteinase- (MMP-) 3, MMP-8, MMP-9, andMMP-13. Furthermore, TCDDmodulated expression of genes
in the plasminogen activator/plasmin system, which regulates MMP activation, and it also increased TIMP1 gene expression.These
findings support the notion that AhR activation by TCDD dysregulates ECM remodeling gene expression and may facilitate ECM
metabolism despite increased liver injury.
1. Introduction
The aryl hydrocarbon receptor (AhR) is a soluble pro-
tein in the basic helix-loop-helix Per/ARNT/Sim family of
transcriptional regulators that contribute to developmental
processes, adaptation to environmental stress, and xenobiotic
metabolism [1–3]. The AhR mediates the toxicity associ-
ated with exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), which is an environmental contaminant and high-
affinity ligand for this receptor [4]. After ligand binding, the
AhR translocates from the cytoplasm to the nucleus, where
it forms a heterodimer with the AhR nuclear translocator
protein (ARNT). The AhR/ARNT complex binds to DNA
at xenobiotic response elements (XREs) and modulates gene
transcription. A growing body of evidence indicates that
the AhR also interacts with other coregulatory proteins in
addition to ARNT and can modulate the expression of
genes that do not contain XREs [5], which underscores
the increasing complexity of AhR-mediated gene regulation.
SuchAhR-dependent changes in gene expression are believed
to underlie most of the toxic responses to TCDD. In the
absence of TCDD, endogenous AhR activation is implicated
in regulating the expression of genes important for a number
of developmental and physiological processes [6, 7].
Emerging evidence implicates a role for AhR signaling
in the deposition and metabolism of extracellular matrix
(ECM) components. The ECM is comprised of a network of
proteins, such as collagens, which are deposited in interstitial
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spaces and providemechanical and structural support to cells
[8]. The ECM also regulates various cellular processes, such
as survival, migration, proliferation, and differentiation, by
modulating tissue stiffness, communicating with the intra-
cellular cytoskeleton, and sequestering and releasing growth
factors [9]. AhR activation by TCDD has been shown to
modulate the expression of ECM proteins, such as collagen
and fibronectin [10–14]. Expression of matrix metallopro-
teinases (MMPs), which are responsible for the degradation
of ECM components, also appears to be targeted by TCDD.
For example, in vitro TCDD treatment was found to increase
MMP expression in human keratinocytes, prostate cancer
cells, and melanoma cells [15–17]. Insight into the effect of
TCDD on ECM maintenance and remodeling also stems
from studies in a zebrafish regeneration model, in which
amputation of the caudal (tail) fin initiates epimorphic regen-
eration accompanied by a wound healing response. Using
this model, Andreasen et al. reported that TCDD treatment
increased the expression of MMP-9 and MMP-13 [18]. In
addition, exposure to TCDD induced a localized fibrosis
in the regenerating fin, where collagen accumulated as an
unorganized fibrotic deposit at the basement membrane.
In a separate study, gene expression analysis revealed that
the largest numbers of genes impacted by TCDD during
fin regeneration were those involved in ECM remodeling
and structure [10]. Collectively, these reports support the
notion that TCDD dysregulates ECM homeostasis, and this
most likely occurs through a mechanism that includes AhR-
mediated changes in gene expression.
Disruptions of ECM metabolism and deposition are
known to impact the development of liver disease [19, 20].
Liver fibrosis is a pathological condition characterized by
the deposition of excessive or abnormal ECM components,
including collagen type I [19]. In the liver, collagen is
synthesized by myofibroblast precursors, namely, hepatic
stellate cells (HSCs). Upon liver injury, HSCs transition from
quiescent, vitamin A-rich cells into activated myofibroblasts,
characterized by increased proliferation, contractility, and
synthesis of collagen type I [21]. One well-established model
system to investigate HSC activation and ECM modulation
is experimental liver fibrosis induced by chronic carbon
tetrachloride (CCl
4
) administration. In the liver, CCl
4
is
metabolized by cytochrome P4502E1 to a trichloromethyl
radical that elicits membrane damage through lipid perox-
idation [22]. Chronic treatment of mice with CCl
4
causes
widespread centrilobular necrosis and inflammation, which
drive HSC activation and the development of fibrosis [23].
We recently found that exposure to TCDD increased liver
damage and HSC activation in mice treated with CCl
4
for 8
weeks [24]. However, TCDD did not increase the deposition
of collagen or the severity of liver fibrosis in CCl
4
-treated
mice, despite increased expression of genes encoding collagen
type I and the potent profibrogenic mediator, transforming
growth factor-𝛽1 (TGF-𝛽1). Results further indicated that
TCDD increased collagenase activity in the liver of CCl
4
-
treated mice. Increased breakdown of ECM in CCl
4
/TCDD-
treated mice could explain why collagen deposition and
fibrosis development were not exacerbated, despite increases
in other endpoints of fibrogenesis.
Collagen biosynthesis begins with the transcription of
procollagen genes and is facilitated by various intercellular
and extracellularmolecules [25]. For example, heat shock pro-
tein-47 (HSP47) is required for proper triple helical fold-
ing and trafficking of procollagen within the endoplasmic
reticulum [26].Anothermolecule, decorin, regulates collagen
fibrillogenesis [27–29]. Lysyl oxidase (LOX) catalyzes cross-
linking of collagen fibers, which marks the last step in
collagen biosynthesis [30].
Collagen breakdown is achieved through the activity
of numerous MMPs. MMP expression is regulated at the
transcriptional level, and these proteins are synthesized
as inactive zymogens called proMMPs [31]. MMP activity
is regulated by enzymatic inhibition and activation. For
example, endogenous tissue inhibitors of metalloproteinases
(TIMPs) inhibit MMP activity. Numerous mechanisms acti-
vate MMPs, including the plasminogen activator/plasmin
system [20]. Plasmin is produced through the cleavage
of plasminogen by tissue plasminogen activator (tPA) and
urokinase plasminogen activator (uPA), and this pathway
is suppressed by plasminogen activator inhibitor-1 (PAI-1).
Plasmin can directly convert proMMPs into enzymatically
active MMPs, and some of these active MMPs can further
activate other proMMPs [32]. MMP activity is central to
the resolution of fibrosis, and scar-associated macrophages
have been identified as an abundant cellular source of these
enzymes in the fibrotic liver [33, 34].
The goal of the present study was to determine how
TCDD treatment impacts the expression of genes related to
ECM synthesis, deposition, and breakdown during chronic
liver injury induced by CCl
4
administration. We measured
gene expression related to collagen synthesis, processing,
and cross-linking and assessed the impact of TCDD on
the organization and dispersion of fibrillar collagens in the
injured liver. Expression of MMPs and the molecules that
activate or inhibit themwere alsomeasured to determine how
TCDDmodulates ECM turnover.
2. Materials and Methods
2.1. Animals. Male C57BL/6 mice (8–10 weeks old; Charles
River, Wilmington, MA) were injected i.p. with 0.5mL/kg
CCl
4
(Sigma-Aldrich, St. Louis, MO) diluted in corn oil or
with corn oil alone (Ctrl) twice a week for 8 weeks. During
the last two weeks of the experiment, mice were treated by
oral gavage once weekly with 20𝜇g/kg TCDD (Cambridge
Isotope Laboratories, Andover, MA) diluted in peanut oil
or with peanut oil vehicle alone (Veh). At the end of the
experiment, animals were euthanized, and liver was either
flash-frozen in liquid nitrogen or fixed in UltraLight Zinc
Formalin Fixative (PSL Equipment, Vista, CA). All animal
experiments were approved by the Institutional Animal Care
and Use Committee at Boise State University and conducted
according to the established policies and guidelines of this
committee.
2.2. Quantitative Real-Time RT-PCR. Total RNA was ex-
tracted using the Omega Bio-Tek E.Z.N.A. Total RNA Kit
BioMed Research International 3
(Norcross, GA) from 20mg of frozen liver tissue. Genomic
DNA was eliminated using the Omega RNase Free DNase
Set (Norcross, GA). RNA concentration and purity were
measured by ultraviolet (UV) absorbance. RNA quality and
elimination of genomic DNA were assessed using an aga-
rose bleach gel [36]. RNA was reverse-transcribed using the
Applied Biosystems High Capacity cDNA reverse transcrip-
tion kit (Thermo Fisher Scientific, Waltham, MA). Gene-
specific primers (Table 1) were used for quantitative real-
timeRT-PCR (qRT-PCR),whichwas performedusing a Light
Cycler 96 Thermocycler and FastStart Essential DNA
Green Master Reaction Mix (Roche, Indianapolis, IN). All
samples were analyzed in duplicate from three mice per
treatment group. Relative quantification was estimated using
ΔΔ𝐶
𝑞
method normalized to GAPDH [37].
2.3. Measurement of Collagen Fibril Organization. Fixed liver
tissue was paraffin-embedded, cut into 2 𝜇m sections, and
stained with Sirius Red as described elsewhere [38]. Bire-
fringence of stained liver tissues was visualized using an
Olympus BX53F polarizing microscope. Photographs were
taken at 600x magnification to focus on septa formation in
the damaged liver of CCl
4
-treated mice. Images were then
converted to 8 bit grayscale and analyzed with FiberFit soft-
ware to calculate fiber dispersion (𝜅) [35]. Ten images were
analyzed from each mouse liver; four mice were evaluated
per treatment group. Septa formation was not detected in the
livers of vehicle- or TCDD-treated mice that did not receive
CCl
4
, and these samples were excluded from the FiberFit
analysis.
2.4. In Situ Zymography. Gelatinase activity was examined
using in situ zymography of zinc-formalin-fixed liver tissue
as described elsewhere [39, 40]. Briefly, tissue sections (8 𝜇m)
were heated at 58∘C for 12 hours then deparaffinized and
rehydrated. DQ-gelatin (Thermo Fisher Scientific) was dis-
solved in reagent-grade water and diluted at 1 : 50 in a 50mM
Tris-HCl buffer containing 150mM NaCl and 5mM CaCl
2
(pH 7.6). Tissue sections were incubated with the DQ-
gelatin solution for 12 hours at 37∘C. Nuclei were stained with
4󸀠,6-diamidino-2-phenylindole (DAPI), and cover slips were
mounted with Permount (Fisher Scientific, Pittsburgh, PA).
Fluorescent images were taken with an EVOS fluorescence
microscope (Thermo Fisher Scientific) with 20x objective.
Fluorescence was quantified using ImageJ software (US
National Institutes of Health) and expressed as a percentage
of the area in the microscope field of view.
2.5.Western Blotting. Frozen liver tissue was homogenized in
50mM HEPES, 150mM NaCl, 10% glycerol, 0.1% Tween 20,





was determined using a DC Protein Assay kit (Bio-Rad
Laboratories, Inc., Hercules, CA), and homogenates were
diluted to 5mg/mL and resuspended in SDS loading buffer
(100mM Tris-Cl pH 6.8, 4% SDS, 0.2% bromophenol blue,
and 20% glycerol) containing 400mM 𝛽-mercaptoethanol.
Table 1: qRT-PCR primers and annealing temperatures used in this
study.
Gene Primer sequence Annealingtemp. (∘C)
Col1a1 FWD: GTCCCTGAAGTCAGCTGCATA 60REV: TGGGACAGTCCAGTTCTTCAT
Col3a1 FWD: CCTGGTGGAAAGGGTGAAAT 62REV: CGTGTTCCGGGTATACCATTAG
Col4a3 FWD: TCCTGGGGAAATGGGAAAGC 64REV: CTGCCTACGGATGGTTCTCC
Col4a5 FWD: TGCTCCTGAGAGATCGGCTT 58REV: GTTATGCTGGTGCACTTGGG
Col6a1 FWD: TCCCACCCACACAGAACAAC 58REV: CACTGAGAGGTGTCGTGTCC
Col6a2 FWD: TGACGCTGTTCTCTGACCTG 58REV: TTGTGGAAGTTCTGCTCGCC
Col6a3 FWD: CTGATGGCACCTCTCAGGAC 58REV: GTCACTTCCAACATCGAGGC
Dcn FWD: AAGGGGGCCGATAAAGTTTC 58REV: CTGGGTTGAAAACCTCCTGC
Lox FWD: CTGCACACACACAGGGATTG 56REV: AGCTGGGGTTTACACTGACC
Mmp2 FWD: ACCCAGATGTGGCCAACTAC 63REV: TACTTTTAAGGCCCGAGCAA
Mmp3 FWD: GTCCTCCACAGACTTGTCCC 65REV: GGGAGTTCCATAGAGGGACTGA
Mmp8 FWD: TACAGGGAACCCAGCACCTA 64REV: GGGGTTGTCTGAAGGTCCATAG





Mmp14 FWD: GCCCTCTGTCCCAGATAAGC 58REV: ACCATCGCTCCTTGAAGACA
Plat FWD: CAGAGATGAGCCAACGCAGA 58REV: TTCGCTGCAACTTCGGACAG
Plau FWD: CATCCAGTCCTTGCGTGTCT 62REV: CCAAGTACACTGCCACCTTCA
Plg FWD: ACTCAAGGGACTTTCGGTGC 58REV: TCAGATACTCGACGCGGTTG
Serpine1 FWD: TTCAGCCCTTGCTTGCCTC 60REV: ACACTTTACTCCGAAGTCGGT
Serpinh1 FWD: GGGAACGGATCGCTCCAAA 67REV: GGACCTGTGAGGGTTTACCAG
Timp1 FWD: CACGGGCCGCCTAAGGAACG 60REV: GGTCATCGGGCCCCAAGGGA
Timp2 FWD: GCCAAAGCAGTGAGCGAGAAG 56REV: CACACTGCTGAAGAGGGGGC
Timp3 FWD: AAGAAAAGAGCGGCAGTCCC 60REV: TTTGGCCCGGATCACGATG
Timp4 FWD: TATGGTAGGTGGGCTGACTGT 64REV: AGTTGAGACAGTGGGAGTAGGA
Samples (25 𝜇g protein/lane) were resolved on a 10% SDS-
polyacrylamide gel, transferred to nitrocellulose, and incu-
bated with the following antibodies purchased from Santa
Cruz Biotech (Dallas, TX): anti-actin (sc-1615), anti-uPa (sc-
59727), or anti-tPA (sc-5239). Blots were then incubated
with HRP-conjugated secondary antibodies, and bands were
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visualized with Pierce ECL Western Blotting Substrate
(Thermo Scientific).
2.6. Immunohistochemistry. Liver tissue was fixed in Ultra-
Light Zinc Formalin Fixative (PSL Equipment, Vista, CA),
paraffin-embedded, and cut into 2 𝜇m sections. Tissue sec-
tions were incubated overnight at 4∘C with an anti-F4/80
antibody (#MCA497R, AbD Serotec, Raleigh, NC) and then
stained with 3,3-diaminobenzidine (DAB) using a commer-
cially available kit (R&D Systems,Minneapolis, MN). Tissues
were counterstained with hematoxylin. Images were taken
with anOlympus BX53 compoundmicroscope at 10x and 20x
magnifications.
2.7. Statistical Analysis. Statistical analyses were performed
using Prism (version 6; GraphPad Software, La Jolla, Ca.).
With the exception of data in Figure 3, all data were evaluated
by two-way analysis of variance followed by Bonferroni’s
post hoc testing to evaluate significance among all possible
pairwise comparisons in the four treatment groups. Statistical
significance between pairwise comparisons is indicated with
letters above the bar for each treatment group. If two groups
share the same letter, then the difference between the means
is not statistically significant at 𝑝 < 0.05. If two means
have different letters, then they are significantly different from
each other at 𝑝 < 0.05. For the analysis of collagen fiber
organization in Figure 3, an unpaired, two-tailed Student’s
𝑡-test was used, and data were also considered significantly
different at 𝑝 < 0.05.
3. Results
3.1. Consequences of TCDD Treatment on Procollagen mRNA
Levels in CCl
4
-Treated Mice. To determine how TCDD treat-
ment impacts procollagen synthesis during chronic liver
injury, we measured the mRNA levels of genes that encode
procollagen type I and III (fibrillar collagens) and types
IV and VI (nonfibrillar collagens). Chronic CCl
4
treatment
significantly increased Col1a1, Col3a1, and Col4a5 in the
mouse liver (Figure 1). Administration of TCDD to CCl
4
-
treatedmice further increased expression ofCol1a1 compared
to mice that received CCl
4
alone. The combination of TCDD
and CCl
4
markedly increased transcript levels of Col6a1,
Col6a2, and Col6a3 compared to mice that did not receive
CCl
4
. Finally, TCDD treatment elevatedCol4a3mRNA levels
in mice that were not treated with CCl
4
, but this increase was
not observed in mice that received both TCDD and CCl
4
.
Collectively, these findings support a general trend in which
exposure to TCDD increases procollagen gene expression in
the liver of CCl
4
-treated mice. Moreover, TCDD impacts the
expression of procollagen isoforms that encode both fibrillar
and nonfibrillar types of collagens.
3.2. TCDD Modulates mRNA Levels of Collagen Processing
Molecules in CCl
4
-Treated Mice. Collagen synthesis requires
not only expression of procollagen genes but also processing
of procollagen, assembly of fibrils, and cross-linking of fibers.









































Figure 1: Consequences of TCDD treatment on collagen mRNA
levels in the liver of CCl
4
-treated mice. Collagen mRNA expression
was measured by qRT-PCR and normalized to GAPDH. Data
represent mean (±SEM) of three mice per treatment group. Within
the data set for each gene, all possible pairwise comparisons were
measured. Means that do not share a letter are significantly different



























Figure 2: TCDD treatment alters expression of collagen processing
molecules in the liver of CCl
4
-treated mice. Transcript levels of
Serpinh1 (HSP47), Dcn (decorin), and Lox (lysyl oxidase) were
measured by qRT-PCR and normalized to GAPDH. Data represent
mean (±SEM) of three mice per treatment group. Within the data
set for each gene, all possible pairwise comparisons were measured.
Means that do not share a letter are significantly different from each
other (𝑝 < 0.05), whereas means that share a letter are not.
To identify how TCDD impacts these events during CCl
4
-
induced liver injury, wemeasured transcript levels of Serpinh1
(HSP47), Lox (LOX), and Dcn (decorin). HSP47 is required
for proper folding and trafficking of procollagen, whereas
decorin and lysyl oxidase contribute to fibril assembly and
fiber cross-linking in the ECM [26, 41]. When TCDD was
administered to CCl
4
-treated mice, Serpinh1 and LoxmRNA
levels increased 4- to 6-fold compared to mice treated
with CCl
4
alone (Figure 2). In contrast, Dcn mRNA levels
BioMed Research International 5
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Figure 3: Exposure to TCDD does not impact collagen fiber organization in the liver of CCl
4
-treated mice. (a) Polarized microscopy
facilitates the visualization of collagen fiber birefringence in liver tissue stained with Sirius Red (600x magnification). Photomicrographs
depict representative fibers in septa of liver from a mouse treated with CCl
4
and peanut oil vehicle (left) or with CCl
4
and TCDD (right).
Scale bars represent 10𝜇m. (b) Collagen network organization was evaluated by analyzing Sirius Red-stained liver tissues with the FiberFit
software application [35]. Ten photomicrographs were evaluated per mouse; four mice were analyzed in each treatment group. Data represent
mean (±SEM) fiber dispersion, 𝑘 (greater 𝑘 values = increase in fiber alignment). No statistically significant changes were found between
treatment groups (𝑝 = 0.36 based on unpaired, two-tailed Student’s 𝑡-test).
were significantly decreased in CCl
4
/TCDD-treated mice.
These results support the notion that TCDD modulates the
expression of genes encoding collagen-processing molecules
during chronic liver injury.
3.3. TCDD Treatment Does Not Affect Collagen Fiber Organi-
zation in the Liver of CCl
4
-TreatedMice. Theobservation that
TCDD altered the expression of ECM processing molecules
in CCl
4
-treated mice led us to speculate that it would subse-
quently impact the fibrillar collagen network. To test this, col-
lagen fibers were visualized in liver tissue stained with Sirius
Red, which aligns with fibrillar collagens and enhances their
birefringence under cross-polarized light [42, 43]. Polarized
microscopy of stained tissue revealed the presence of thick,
strongly birefringent yellow fibers in the septa of livers from
CCl
4
-treated mice (Figure 3(a)). Based on visual inspection,
TCDDhadno overt impact on fiber appearance.The effects of
TCDD on collagen fiber organization were further evaluated
using the free software application, FiberFit, which uses
image processing techniques to analyze two-dimensional
images of fiber networks [35]. Results indicate that TCDD
had no effect on fiber dispersion, which is a measure of
fiber network disorder (Figure 3(b)). Hence, despite the
TCDD-mediated increase in expression of genes encoding
procollagen and collagen-processing molecules, TCDD did
not appear to impact collagen organization in the ECM of
CCl
4
-treated mice. No collagen fibers were detected in either
vehicle- or TCDD-treated mice that did not receive CCl
4
(data not shown), and these samples were excluded from the
FiberFit analysis.
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Figure 4: Effects of TCDD treatment on mRNA levels of MMPs
in the liver of CCl
4
-treated mice. MMP mRNA expression was
measured by qRT-PCR and normalized to GAPDH. Data represent
mean (±SEM) of three mice per treatment group. Within the data
set for each gene, all possible pairwise comparisons were measured.
Means that do not share a letter are significantly different from each
other (𝑝 < 0.05), whereas means that share a letter are not.
3.4. Expression of ECM Remodeling Enzymes Is Elevated in
the Presence of TCDD. ECM maintenance requires not only
the synthesis and deposition of matrix molecules but also
their degradation and turnover, which is regulated by the
proteolytic activity of MMPs. MMP expression is largely
regulated at the transcriptional level [44]. To determine
how TCDD treatment impacts MMP gene expression in the
liver of CCl
4
-treated mice, we measured transcript levels of
mouse MMPs known to be important in chronic liver injury.
Mmp8 and Mmp13 encode enzymes that function primarily
as collagenases, and expression of these genes was markedly
increased by TCDD regardless of CCl
4
treatment (Figure 4).
Mmp2 and Mmp9 are referred to as gelatinases, and they
degrade not only gelatin but also collagen type IV, laminin,
elastin, and fibronectin [44]. While TCDD had no effect
on Mmp2 transcript levels, it increased Mmp9 expression in
CCl
4
-treated mice. Likewise, the combination of TCDD and
CCl
4
increased Mmp14 (membrane-type MMP) expression
compared to mice treated with TCDD alone, although this
increase was modest.Mmp3 (stromelysin) mRNA levels were
significantly higher in TCDD-treated mice, regardless of
CCl
4
treatment. Generally speaking, these results support




3.5. TCDD Increases Gelatinase Activity in the Liver of CCl
4
-
Treated Mice. MMP activity is central to ECM remodeling
and is implicated in both the promotion and attenuation of
liver injury [20]. We recently found that TCDD treatment
increased collagenase activity in the liver of CCl
4
-treated
mice [24]. During fibrotic liver injury, collagenases cleave the
native helix of fibrillar collagens to produce gelatin, which
can be degraded by MMPs, namely, MMP-2 and MMP-
9 [45]. We used in situ zymography to measure gelatinase
activity in the liver. Whereas gelatinase activity was barely
detectable in mice treated with CCl
4
/Veh (Figure 5(a)), it
was significantly induced when TCDD was administered to
CCl
4
-treated mice (Figure 5(b)). When administered alone,
TCDD did not increase gelatinase activity. In fact, there was
no detectable gelatinase activity in either vehicle- or TCDD-
treated mice in the absence of CCl
4
(data not shown).
3.6. Consequences of TCDD Treatment on TIMP mRNA
Expression in CCl
4
-Treated Mice. MMP activity is controlled
by enzymatic activation and inhibition [31]. The activity of
MMPs can be inhibited by four homologous members of the
TIMP family. TIMP1 is a strong inhibitor of many MMPs,
but the gelatinases MMP-2 and MMP-9 are also inhibited
by other TIMPs. For example, TIMP2, TIMP3, and TIMP4
can inhibit MMP-2 activity, and TIMP3 inhibits MMP-9
[31]. Analysis of TIMP gene expression revealed that TCDD
treatment increased Timp1 but had no impact on Timp2,
Timp3, or Timp4 regardless of CCl
4
treatment (Figure 6).
Hence, modulation of TIMP gene expression by TCDD
appears to be limited to Timp1.
3.7. TCDD Treatment Modulates Expression of Molecules in
the Plasminogen Activator/Plasmin System. MMP activation
is regulated through numerous mechanisms, including the
plasminogen activator/plasmin system, in which tPA and
uPA mediate the conversion of plasminogen to plasmin,
which directly activates numerous proMMPs [20]. PAI-1 sup-
presses MMP proteolytic activity by inhibiting tPA/uPA, and
PAI-1 gene is known to be regulated by AhR activity [46–48].
To determine how TCDD impacted this pathway of MMP
activation, we measured expression of Plg (plasminogen),
Plat (tPA), Plau (uPA), and Serpine1 (PAI-1). TCDD induced
a modest, yet statistically significant, decrease in Plg mRNA
levels in CCl
4
-treated mice (Figure 7(a)). Levels of Plat and
Plau expression were markedly elevated in CCl
4
/TCDD-
treated mice. A corresponding increase in the Plat-encoded
protein tPa was measured in CCl
4
/TCDD-treated mice,
whereas no changes were detected in the expression of uPa,
which is encoded by Plau (Figure 7(b)). Finally, exposure to
TCDD increased PAI-1 (Serpine1) gene expression regardless
of CCl
4
-treatment (Figure 7(a)). Hence, these observations
indicate that TCDD treatment modulated the expression of
the plasminogen activator/plasmin system.
3.8. TCDD Treatment Increases the Localization of Hepatic
Macrophages around Fibrotic Scars in the Liver of CCl
4
-Treated
Mice. Macrophages contribute to ECM remodeling during
both the injury and recovery phase of CCl
4
-induced liver
fibrosis [49] and are an abundant source of MMP-9 and
MMP-13 [33, 50]. Scar-associated macrophages populate the
fibrotic scar during injury and repair, produce MMPs, and
secrete cytokines that induce MMP production in other cells
[51]. Given that TCDD treatment increasedMMP expression
and activity, we investigated the possibility that TCDD
increased the prevalence of hepatic macrophages around
scar areas in the fibrotic liver. As shown in Figure 8, CCl
4
administration elicited the infiltration of inflammatory cells




mice compared to CCl
4
/Veh-treated mice.
































Figure 5: TCDD treatment increases gelatinase activity in the liver of CCl
4
-treated mice. (a) In situ zymography of zinc-buffered, formalin-
fixed liver tissue usingDQ-gelatin. Green fluorescence indicates gelatinase activity; nuclei were stained withDAPI. Photomicrographs (100x
magnification) are representative of three mice per treatment group. Scale bars represent 400 𝜇m. (b) Quantification of gelatinase activity
based on the percentage of green fluorescence coverage per field of liver tissue. Ten fields were analyzed per mouse; three mice were evaluated
per treatment group. Data represent mean (±SEM) of three mice per treatment group. All possible pairwise comparisons were measured for
statistical significance. Means that do not share a letter are significantly different from each other (𝑝 < 0.05), whereas means that share a letter
are not.
4. Discussion
The present study investigated the consequences of TCDD
treatment on expression of molecules involved in colla-
gen biosynthesis and ECM metabolism during chronic
liver injury. We recently reported that exposure to TCDD
increased HSC activation and mRNA levels of TGF-𝛽1
and collagen type I in the injured liver without increasing
hepatic collagen content or exacerbating fibrosis [24]. This
led us to speculate that TCDD treatment may dysregulate
ECM remodeling activities, including collagen synthesis or
turnover.
During fibrosis, the collagen content in the liver can
increase up to tenfold [52]. Our results indicate that TCDD
treatment alone increased Col1a1 and Col4a3. This obser-
vation corroborates other reports in which exposure to
TCDD increased collagen types I and IV [11–14, 53]. In
CCl
4
/TCDD-treated mice, there was a marked increase in
expression of Col3a1, Col4a5, Col6a1, Col6a2, and Col6a3
compared to Ctrl/Veh-treated mice. Collagen type III is
structurally similar to collagen type I and is the first collagen
to increase during chronic liver disease [54]. Collagen type
IV is the primary component of basement membranes, and
its expression increases during fibrosis [55]. Collagen type VI
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Figure 6: Consequences of TCDD treatment onTIMPmRNA levels
in the liver of CCl
4
-treated mice. TIMP mRNA expression was
measured by qRT-PCR and normalized to GAPDH. Data represent
mean (±SEM) of three mice per treatment group. Within the data
set for each gene, all possible pairwise comparisons were measured
for statistical significance. Means that do not share a letter are
significantly different from each other (𝑝 < 0.05), whereas means
that share a letter are not.
is also upregulated in liver fibrosis and has been shown to
stimulate DNA synthesis and inhibit apoptotic cell death in
HSCs in vitro [56]. This is intriguing because we previously
reported that exposure to TCDD increases HSC proliferation
in vitro [57] and increases HSC activation markers in the
liver of CCl
4
-treated mice [24]. It is possible that increased
expression of collagen type VI, as well as other types of
collagen, contributes to the effects of TCDD in the CCl
4
model system.
The finding that certain collagen genes were upregulated
by TCDD treatment only, while others were increased by
the combination of TCDD and CCl
4
, implies that the AhR
may differentially regulate gene expression in the healthy
and injured liver. It is well established that most, if not
all, of the biochemical and toxic effects of TCDD occur
through the AhR [2, 58]. Increasing evidence supports a
role for endogenous AhR signaling in regulating collagen
deposition, including the discovery that AhR knockout mice
develop liver fibrosis and have elevated TGF-𝛽1 and collagen
expression [59–61]. In addition, it was recently reported that
AhR knockdown increased Col1a1 and Col4a4 mRNA levels
in retinal pigment epithelial cells and choroidal endothelial
cells [62]. Collectively, these findings implicate a role for
AhR activity in regulating collagen gene expression. Future
studies that investigate how AhR knockdown impacts gene
expression during chronic liver injury will expand our under-
standing of how the AhR regulates ECM remodeling during
states of health and disease. Furthermore, the use of mice in
which the AhR is conditionally depleted from discrete liver
cell populations could help identify which cells are directly
targeted by TCDD to produce ECM dysregulation.
Not only did TCDD increase the expression of collagen
genes but it also modulated gene expression for several
key proteins involved in collagen synthesis. For example,
administration of TCDD to CCl
4
-treated mice increased
gene expression of HSP47, which resides in the endoplasmic
reticulum and is involved in the folding and shuttling of
collagen molecules to the Golgi [63]. Increased HSP47 levels
reportedly contribute to fibrosis by facilitating the exces-
sive assembly and intracellular processing of procollagen
molecules, leading to fibrotic lesions [64]. Furthermore,
suppression of HSP47 expression was reported to reduce
collagen accumulation and delay fibrotic progression [65].
Both procollagen and HSP47 gene expression are regulated
by TGF-𝛽1 [66]. We previously found that TGF-𝛽1 gene
expression was increased in CCl
4
/TCDD-treated mice and
speculate that this could drive HSP47 and Col1a1 expression
in our model system. However, TCDD treatment was shown
to suppress bothCol1a1 andHSP47 gene expression during fin
regeneration in zebrafish, despite increased TGF-𝛽1 expres-
sion [10, 18].
Decorin is a secreted proteoglycan that has a dual role
in liver fibrosis. First, it functions as a naturally occurring
TGF-𝛽1 antagonist, and its genetic ablation has been shown
to increase ECM deposition, impair matrix degradation, and
increase HSC activation [67]. Second, decorin facilitates the
development of normal collagen morphology by binding to
the collagen triple helix and preventing the lateral fusion of
fibrils [28]. We found that TCDD suppressed decorin gene
expression in CCl
4
-treated mice. Other studies demonstrate
a possible role for AhR signaling in decorin expression. For
instance, decorin expression was increased in fibroblasts and
vascular smooth muscle cells from AhR knockout mice [68,
69].
LOX mediates the cross-linking of collagen fibers which
is important for collagen organization and perhaps also for
conferring resistance to proteolytic degradation by MMPs
[70]. Consistent with this role of LOX, administration of
the irreversible LOX inhibitor 𝛽-aminopropionitrile (BAPN)
to CCl
4
-treated mice was recently found to reduce collagen
cross-linking and produced fibrotic septa with less organized
collagen fibers [30]. Our finding that TCDD increased LOX
expression in CCl
4
-treated mice could possibly be explained
as a compensatory response to increased collagen synthesis,
as could the TCDD-induced increase in HSP47. It is worth
noting that Andreasen et al. reported that TCDD treatment
suppressed not only LOX2 and HSP47 expression during
zebrafish fin regeneration but also prolyl-4-hydroxylase 𝛼1
and 2, which help stabilize collagen cross-links [10]. Based
on the role of these molecules in collagen processing and
organization, their reduced expression may underlie the
accumulation of disorganized collagen observed in the regen-
erating fin tissue [18]. In contrast, we found no evidence that
TCDD impacted collagen fiber organization in the liver of
CCl
4
-treated mice. Increased expression of LOX and HSP47,
as well as decreased expression of decorin, could be one
possible explanation for this observation.
One of the most consistently reported consequences of
TCDD treatment on ECM remodeling is increased MMP
expression [71]. TCDD treatment increases the expression
and activity of MMPs in numerous and diverse cell types,
including keratinocytes, macrophages, and endometrial cells
[72–74]. In the zebrafish model of fin regeneration, TCDD
BioMed Research International 9















































































Ctrl/Veh Ctrl/TCDD CCl4/TCDDCCl4/Veh Ctrl/Veh Ctrl/TCDD CCl4/TCDDCCl4/Veh
(b)
Figure 7: Exposure to TCDD modulates expression of genes in the plasminogen activator/plasmin system. (a) Transcript levels of Plg
(plasminogen), Plat (tPA), Plau (uPA), and Serpine1 (PAI-1) were measured by qRT-PCR and normalized to GAPDH. Data represent mean
(±SEM) of three mice per treatment group. Within the data set for each gene, all possible pairwise comparisons were measured for statistical
significance. Means that do not share a letter are significantly different from each other (𝑝 < 0.05), whereas means that share a letter are
not. (b) uPa and tPa protein levels were measured byWestern blot. Band densitometry was normalized to actin and expressed as fold change
relative to the Ctrl/Veh treatment group. Means that do not share a letter are significantly different from each other (𝑝 < 0.05).
upregulatedMMP-13 [10]. Similarly, TCDD increased expres-
sion of MMP-13, as well as other MMPs, in the fetal
mouse heart [53].These reports support our observation that
TCDD increasedMmp3,Mmp8,Mmp9,Mmp13, andMmp14
genes in the mouse liver. MMP-8 and MMP-13 function
primarily as collagenases, and these were robustly increased
by TCDD regardless of CCl
4
treatment, which corroborates
our previous finding that TCDD increases collagenase activ-
ity in the liver of CCl
4
-treated mice [24]. During ECM
breakdown, MMPs with collagenase activity will partially
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Figure 8: TCDD treatment increases localization of F4/80+ macrophages around fibrotic scar. Immunohistochemistry was performed to
identify hepatic macrophages (F4/80+ cells) localized around the fibrotic scar in CCl
4
-treated mice (20x magnification). Scale bars represent
50 𝜇m.
denature collagen, resulting in the production of gelatin,
which is metabolized primarily by the gelatinases MMP-2
and MMP-9 [20]. Decreased gelatinase activity, particularly
MMP-2, is associated with increased liver fibrosis develop-
ment [75]. The increase in gelatinase activity we observed
in CCl
4
/TCDD-treated mice could reflect a compensatory
response to increased collagenase activity. Furthermore,
TCDD also increased expression of MMP-3 (stromelysin)
and MMP-14 (membrane-type), both of which reportedly
exhibit some collagenase and gelatinase activity.
MMP activity is inhibited through interactions with
TIMP proteins, as well as other endogenous inhibitors [76].
TIMP1, in particular, is associated with ECM proteolysis
during fibrosis, and Timp1−/− mice display increased liver
injury, inflammation, and fibrosis following CCl
4
treatment
[77]. TIMP1 is a strong inhibitor of most MMPs except
some of the membrane-type MMPs. However, the gelatinase
MMPs are inhibited by other TIMPs as well. Specifically,
TIMP1 and TIMP3 inhibit MMP-9, and TIMPs 2, 3, and
4 inhibit MMP-2 [78]. In the CCl
4
model system, TCDD
treatment increased TIMP1 but had no effect on expression
of TIMPs 2, 3, or 4. Thus, it is possible that the expression
of TIMPs in CCl
4
/TCDD-treated mice was not sufficient to
counteract MMP activity. Other studies have reported that
TIMP expression is modulated by in vitro and in vivo TCDD
exposure as well [10, 79–81].
Our results demonstrate that TCDD treatment produced
changes in the plasminogen activator/plasmin system that
modulates MMP activation. TCDD was found to modestly
but significantly decrease plasminogen expression in CCl
4
-
treated mice. Because MMPs are activated by plasmin, which
is produced from plasminogen, this would presumably lead
to decreased MMP activation. Given that TCDD increased
both collagenase and gelatinase activity in the CCl
4
model
system, it is possible that the observed decrease in plas-
minogen gene expression was not physiologically relevant.
It is also possible that increased expression of tPA and uPA
compensated for any decrease in plasminogen expression.
The TCDD-mediated increase in uPA gene expression cor-
roborates another report showing that TCDD upregulated
uPA protein in a human keratinocyte cell line [82]. It is
interesting to note that this TCDD-induced increase in uPA
appeared to occur through a posttranscriptional mechanism
that included changes in mRNA stability [82, 83]. We found
no significant increase in uPa protein expression among all
four treatment groups in our study, although protein levels of
tPa were markedly increased in CCl
4
/TCDD-treated mice.
The Serpine1 gene that encodes PAI-1 is recognized as an
AhR-regulated target gene. It is transcriptionally induced by
TCDD through a mechanism that involves heterodimeriza-
tion of the AhR with the transcription factor, KLF-6, and the
recruitment of this complex to a nonconsensus XRE [46–
48]. We found that TCDD treatment increased PAI-1 gene
expression regardless ofCCl
4
treatment andpresume that this
reflects a direct effect of TCDD through AhR-regulated gene
expression. However, it is also possible that increased PAI-1
expression by TCDD occurs as a consequences of activation
of the TGF-𝛽1 pathway, as PAI-1 is an early TGF-𝛽1 activated
gene [84], and other studies have described crosstalk between
the AhR and TGF-𝛽1 signaling axes [69, 85]. Based on our
finding that TCDD did not suppress collagenase or gelatinase
activity in CCl
4
-treated mice, it is possible that increased
PAI-1 expression in CCl
4
/TCDD-treated mice failed to offset
increased tPA/uPA activity. However, MMPs can also be acti-
vated through nonplasmin pathways, which leaves open the
possibility that MMP activation is increased in CCl
4
/TCDD-
treated mice, despite inhibition of the plasminogen activa-
tor/plasmin system by PAI-1.
The observation that TCDD treatment may enhance
the prevalence of scar-associated macrophages is intriguing
because these cells are a rich source of MMPs and may
contribute to both the injury and regression phase of fibrosis
induced by CCl
4
[49]. We have previously found that TCDD
treatment increases liver damage and inflammation in CCl
4
-
treated mice [24], yet the direct cellular targets of TCDD
in this model system have not been determined. It is pos-
sible that increased hepatocellular necrosis in CCl
4
/TCDD-
treated mice evokes a heightened inflammatory response,
resulting in increased numbers of infiltrating neutrophils and
monocytes/macrophages. However, it is also conceivable that










as source of MMPs?
Plasminogen activator/plasmin system
↑ uPa protein
↑ Col1a1, ↑ Col3a1, ↑ Col6a3 mRNA levels
↑ Lox, ↑ Hsp47, ↓ Dcn mRNA levels
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Figure 9: Summary of the consequences of TCDD treatment on




TCDD treatment directly modulates hepatic macrophages
in CCl
4
-treated mice. Further investigation is warranted to
identify the cellular source of increased MMP activity and
determine how TCDD treatment impacts the localization
of resident macrophages and infiltrating monocytes to the
fibrotic scar.
In conclusion, results from this study demonstrate that
AhR activation by TCDD modulates ECM remodeling dur-
ing chronic liver injury, although the precise mechanism
remains unclear. At least three interrelated components of
ECM homeostasis could be targeted by TCDD: collagen syn-
thesis, ECM metabolism, and regulation of enzyme activity
by the plasminogen activator/plasmin system. As summa-
rized in Figure 9, TCDD treatment increased expression
of procollagen genes and altered expression of molecules
involved in collagen processing and maturation. Further-
more, TCDD enhanced gelatinase activity, increased mRNA
levels of several MMPs, and increased the localization of
hepatic macrophages to the fibrotic scar. Finally, TCDD
treatment had multiple effects on the plasminogen activa-
tor/plasmin system. Future studies will be needed to distin-
guish between TCDD-induced changes that directly impact
ECM remodeling and changes that occur as secondary,
compensatory responses to system perturbations.
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